Background Residual mural thrombus on severely damaged arterial wall is very thrombogenic. We tested the hypothesis that direct thrombin inhibition will block thrombus growth on fresh thrombus better than indirect thrombin inhibition, cyclooxygenase inhibition, or both.
Inhibition of Growth of Thrombus on
Fresh Mural Thrombus Background Residual mural thrombus on severely damaged arterial wall is very thrombogenic. We tested the hypothesis that direct thrombin inhibition will block thrombus growth on fresh thrombus better than indirect thrombin inhibition, cyclooxygenase inhibition, or both.
Methods and Results A fresh mural thrombus was formed by directly perfusing fresh porcine blood for 5 minutes over severely damaged arterial wall at a high shear rate in a well-characterized ex vivo perfusion system. The average platelet (P) and fibrinogen (F) deposition (D) achieved in 5 minutes were 382±32x106 platelets/cm2 and 296±36x 1012 fibrinogen molecules/cm2, respectively. Thrombus growth on the fresh mural thrombus was quantitated by directly perfusing blood from pigs with`In-labeled platelets and 1251-labeled fibrinogen for an additional 5 minutes over the preformed mural thrombus. Treatment included recombinant hirudin (1 mg/kg per hour IV) as a probe for thrombin, aspirin (5 mg/kg IV) as a platelet inhibitor of cyclooxygenase, heparin (moderate, 100 IU/kg per hour IV; high-dose, 250 IU/kg per hour IV) as an indirect thrombin inhibitor, and heparin (100 IU/kg per hour) plus aspirin (5 mg/kg IV). Thrombus growth as mea-P latelet-rich thrombus formation on a disrupted atherosclerotic plaque is an important pathogenetic factor in the development of acute coronary syndromes.1-6 Thrombin generation and platelet aggregation play key roles in the progression of coronary thrombosis. 37 The goal of treatment in unstable angina and after thrombolysis for acute myocardial infarction is to block growth of thrombus and to prevent new occlusions.
Angiographic studies8,9 stressed the importance of residual mural thrombus for predisposition to rethrombosis after thrombolysis. Factors that may contribute to rethrombosis include reexposure of damaged vessel wall,10 thrombin bound to clot or arterial wall matrix,11,2 platelet secretory products,13 and thrombolysisinduced platelet activation or stimulation of thrombin generation.14 Failure of medical therapy in acute coronary syndromes most often occurs within the first days sured by labeled PD (x106/cm2) and FD (x1012 molecules/ cm2) was mildly but not significantly reduced by aspirin (1034±92 and 436±78, respectively) compared with baseline (1113±67 and 545±52, respectively). Inhibition of thrombus growth with heparin was dose dependent. A regression analysis showed an inverse correlation of PD and FD with mean plasma heparin concentrations (r= -.81, P=.0001 and r= -.49, P=.0007, respectively). Recombinant hirudin led to a profound inhibition of thrombus growth (PD, 30+12; FD, 109±21), which was significant compared with all groups, even the highest dosage of heparin (250 IU/kg per hour).
Conclusions Specific thrombin inhibition markedly inhibits platelet and fibrinogen deposition onto fresh mural thrombus at a high shear rate. Aspirin alone or in combination with heparin has little effect on evolving thrombosis. Heparin dose dependently reduces thrombus growth, but even the highest dosage is less effective than hirudin. Thrombin appears to be the primary activator of platelets by fresh thrombus. (Circulation. 1994;90:2432-2438.)
Key Words * thrombosis * atherosclerosis * reocclusion * antithrombotics * hirudin of treatment.15 Increased thrombin generation16 may persist beyond the acute event of thrombolytic treatment and lead to late reocclusions despite current antithrombotic treatment.17 '18 We used our porcine ex vivo perfusion model'9 to study the growth of arterial thrombus onto preformed mural thrombus under controlled rheologic conditions corresponding to a moderate coronary stenosis. We hypothesized that specific direct antithrombin therapy with hirudin would inhibit growth of thrombus onto fresh thrombus better than indirect antithrombin or cyclooxygenase inhibition with current medical therapies (aspirin, heparin, or both). Our results suggest that specific thrombin inhibition profoundly blocks the growth of thrombus on fresh arterial thrombus.
Methods
To quantitatively study the growth of arterial thrombus onto preformed fresh thrombus induced by severely injured arterial wall, we modified our porcine ex vivo perfusion system19-2' as described below using fresh blood to measure "'In-labeled platelets and`251-labeled fibrinogen depositions onto severely injured arterial wall (mural thrombus) and onto preformed unlabeled mural thrombus (growth of thrombus). 
Perfusion Chamber
We used our previously characterized perfusion chamber, which mimics the cylindrical shape of the blood vessels.19'21 '23 The substrate was placed in the lateral wall of the lumen of the blood channel of the perfusion chamber and was directly exposed to fresh blood as described below. In the present study, we used a chamber with an internal diameter of 0. 
Preparation of Vessel Segments
Pig tunica media prepared from aortas harvested from healthy untreated pigs were used as a model of severe arterial wall damage. 28 The aortas were obtained fresh, cleaned of the surrounding connective tissue, immediately deep-frozen in liquid nitrogen, and stored at -70°C. Before the experiments, the aortas were thawed in phosphate-buffered saline (PBS) at 4°C, opened longitudinally, and cut into 25 x 10-mm segments. The intima with a thin portion of the subadjacent media was removed, leaving the substrate with the major portion of the remaining media.
Perfusion Conditions
Tunica media vessel wall segments were mounted in the chamber and perfused with PBS solution in a water bath at 37°C for 60 seconds. Then, blood was perfused through the chamber for a selected period of time, followed by perfusion with buffer for 60 seconds to clear away unattached cells and blood.
Quantitation of Thrombus Growth
To quantitate growth of thrombus on fresh thrombus formed on tunica media, we modified the previously described perfusion conditions21 by using blood from two pigs in the same experiment. One pig with unlabeled blood was used to form a fresh thrombus. The second pig with "'.In-labeled platelets and '-SI-labeled fibrinogen was used to quantitate the growth of thrombus under identical flow conditions (Fig 1) .
After the preperfusion period with buffer, unlabeled blood from pig A was passed through the chamber at a flow rate of 10 mL/min for 5 minutes to create a fresh thrombus (formed on severely injured arterial wall). Then, the growth of thrombus on fresh (unlabeled) thrombus as a substrate was measured using blood from pig B containing autologous "'.Inlabeled platelets and 1251-labeled fibrinogen under the same flow conditions for 5 minutes (thrombus growth, Fig 1) . The changes from buffer to blood A, blood A to blood B, and blood B to buffer were achieved manually by three-way stop cocks without introducing stasis or air in the chamber. One stop cock was used to discard blood and buffer before autologous blood was recirculated through the jugular vein.
Evaluation of the Perfusion Model of Thrombus Growth
We have previously shown that the rate of platelet deposition on severely damaged vascular wall at high shear rates is characterized by a first-order rate constant. 
Results

Model of Thrombus Progressiom
We have developed a perfusion model of arterial thrombosis for the study of growth of thrombus on fresh mural thrombus, which is preformed on severely injured arterial wall (Fig 2) . All (Fig 2A and 2B) . Effect of Treatment Regimens on Thrombus Progression
The growth of thrombus on preformed fresh thrombus (n=32) and the effect of various treatments on the growth of thrombus (n=12 each) are shown in Fig 3A and 3B.
The mean deposition of`1In-labeled platelets and 1251-labeled fibrinogen molecules on a fresh thrombus at high shear rate in pigs treated with aspirin compared with baseline was not significantly different.
Platelet and fibrinogen depositions in those treated with heparin 100 IU/kg per hour and the combination of heparin 100 lU/kg per hour and aspirin were moderately and significantly lower compared with baseline but and compared with those treated with lower doses of heparin (100 IU/kg per hour, P<.01 and =.13, respectively). In fact, log of platelet deposition showed a strong and significant inverse relation with aPTT levels (r= -.80, P=.0001) and mean plasma heparin concentrations (r= -.81, P=.0001; Fig 4A) . Similarly, molecules of fibrinogen deposited were inversely correlated with aPTT (r= -.44, P=.003) and mean plasma heparin concentrations (r= -.49, P=.0007; Fig 4B) . Hirudin significantly reduced platelet and fibrinogen deposition, even compared with the highest concentration of heparin (P<.001 and <.001, respectively).
To assess the level of anticoagulation in the different experimental groups in this study, we performed the aPTT test on all pigs. Heparin levels were also directly measured using anti-factor Xa activity test. Table 1 presents mean aPTT values and heparin levels obtained from hourly samples taken over a 6-hour period. At similar aPTT levels, hirudin was more effective in reducing platelet and fibrinogen deposition on a fresh thrombus than heparin. Note that baseline perfusions of all experimental groups were carried out at a low level of anticoagulation (mean aPTT ratio, <1.5 with 50 IU/kg heparin). Laboratory Data Platelet count, fibrinogen levels, and hematocrit were assessed every hour during baseline perfusions and during the treatment period. There was a slight nonsignificant reduction in platelet count from 447+ 18 to 421 15 x103/,uL during the treatment phase compared with the baseline perfusion period. Fibrinogen levels and hematocrit remained unchanged from 259+±23 to 253+±21 mg/dL and from 31±0.8% to 30±1.0%, respectively. Platelet counts, fibrinogen levels, and hematocrit did not differ significantly between treatment groups.
Discussion
This study demonstrates the primary thrombin dependence of growth of thrombus as shown by the therapeutic probe hirudin in blocking growth of thrombus. This is consistent with the increased thrombin content of thrombus adjacent to severely injured arterial wall,32 the increased fibrinogen/fibrin deposition in the layers of thrombus immediately adjacent to severely injured arterial wall,33 the binding of active thrombin to fibrin and arterial wall matrix, and the masking of receptors to antithrombin III and heparin cofactor II on thrombin bound to fibrin.l11,234
This study supports the hypothesis that platelet and fibrinogen depositions onto fresh mural thrombus at high shear rate are primarily thrombin dependent and decrease with increasing antithrombin activity. Platelet and fibrinogen depositions induced by fresh mural thrombus were lowest in pigs treated with the specific thrombin inhibitor hirudin, which does not inhibit other platelet activators but completely abolished growth of thrombus. The antithrombin effect of heparin was incomplete at usual therapeutic doses but improved at very high doses. Recombinant hirudin (r-hirudin) was more effective than high-dose heparin at lower aPTT levels. The effect of aspirin (alone or combined with heparin) on thrombus growth at high shear was mild and not significant.
In acute coronary syndromes and after reperfusion, a fresh mural thrombus over atherosclerotic plaque may contribute to residual stenosis and stimulate thrombus growth to total occlusion. This ex vivo perfusion model in the pig is useful for quantitating the growth of thrombus onto a preformed thrombus and for testing the efficacy of various antithrombotic treatments in blocking growth of thrombus.
Thrombus formation on areas of severely injured artery is greatly dependent on local thrombin produc- Heparin level, lUhmI FIG 4 . Plots of relation between heparin levels (IU/mL) and log of platelet (A) and log of fibrinogen (B) depositions during growth of thrombus onto a mural thrombus in pigs treated with different heparin doses. The significant inverse relations are shown. 
Conclusions
This study suggests that the growth of a thrombus on a vascular surface covered with fresh thrombus appears to be primarily thrombin mediated. Specific thrombin inhibition with hirudin has a dramatic inhibitory effect on platelet and fibrinogen deposition during growth of mural thrombus and may be a superior treatment strategy for acute coronary syndromes and prevention of reocclusion after thrombolytic therapy. Future studies need to address the optimal duration of antithrombin therapy.
